No enough information available in matter of patient on Rivaroxaban a direct factor Xa inhibitor specially in Saudi population. In addition, patient with chronic kidney disease, valvular atrial fibrillation or liver disease must not be considered for such therapeutic change.
(2022). Safety and Mortality: Monitoring the Patients on Rivaroxaban. Cardiovascular Research Prove Journal, 6(2), -. doi: 10.21608/cvrepj.2022.351489
MLA
. "Safety and Mortality: Monitoring the Patients on Rivaroxaban", Cardiovascular Research Prove Journal, 6, 2, 2022, -. doi: 10.21608/cvrepj.2022.351489
HARVARD
(2022). 'Safety and Mortality: Monitoring the Patients on Rivaroxaban', Cardiovascular Research Prove Journal, 6(2), pp. -. doi: 10.21608/cvrepj.2022.351489
VANCOUVER
Safety and Mortality: Monitoring the Patients on Rivaroxaban. Cardiovascular Research Prove Journal, 2022; 6(2): -. doi: 10.21608/cvrepj.2022.351489
)
View on SCiNiTO